Next, we describe our phase I/IIa clinical trial protocol to investigate the safety and efficacy of RNK001 cells in patients with AML or myelodysplastic syndrome with excess blasts (MDS-EB2) with residual disease, with and without in vivo IL2 cytokine support (EudraCT 2019-001929-27). The gene discussed is IL2; the disease is acute myeloid leukemia.